DAEJEON, South Korea, May 11, 2022 /PRNewswire/ — PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotechnology company focused on the development of next-generation antibody therapeutics, today announced that Dr. Jin San YooPresident and CEO of PharmAbcine is invited to participate in the Jefferies Global Healthcare conference on June 8-10, 2022 in New York, NY.
Also, Dr. Yoo and Dr. Hyunsun ParkChief Operating Officer and Chief Business Officer of PharmAbcine, will participate in BIO International Convention (BIO UNITED STATES) finished June 13-16, 2022 in San Diego, California.
The event details are as follows:
Event: Jefferies Global Healthcare Conference 2022
Date: June 8-10, 2022
Event calendar : https://www.jefferies.com/IdeasAndPerspectives/ConferenceList/Investment-Conferences/159
Event: International BIO Convention (BIO UNITED STATES)
Date: June 13-16, 2022
Registration: https://www.bio.org/events/bio-international-convention/registration
Request a partnership with PharmAbcine:
https://login.partnering.bio.org/inova-business-platform/webclient/#/bio/10800/company/137494
At the Jefferies Global Healthcare Conference, Dr. Yoo will hold meetings with registered members of the investment community to research investment opportunities and discuss current trends in drug development and the healthcare industry. Registered members will include leading global leaders, institutional investors and private equity investors.
Following the meetings at Jefferies, Dr. Yoo and Dr. Park will attend the BIO International Convention to meet with global pharmaceutical companies. They will showcase PharmAbcine’s core technology and pipeline assets to discuss potential licensing and co-development opportunities with global biotech and pharmaceutical companies attending the event.
The Company’s pipeline assets include olinvacimab, PMC-403 and PMC-309.
Olinvacimab, a fully human anti-VEGFR2 (vascular endothelial growth factor receptor 2) antibody, is the Company’s lead pipeline and is in a combined Phase IIa trial in mTNBC (triple breast cancer). metastatic negative) and a single phase IIa study in non-responder bevacizumab-rGBM (recurrent glioblastoma). The combined mTNBC olinvacimab-pembrolizumab study had the first patient to December 2021 and actively recruits patients in Australia. The mono phase II study on olinvacimab has enrolled 18 patients out of a total of 36 at the date of April 2022 and continues in Australia and the United States
PMC-403 is a fully human TIE2 activating antibody designed to stabilize and repair pathologically leaky blood vessels in a wide range of indications. PMC-403 is currently under development to treat neovascular indications in ophthalmology, including AMD (age-related macular degeneration), DR (diabetic retinopathy) and DME (diabetic macular edema). The distinct mechanism of PMC-403 allows it to be used in patients who show little or no response to existing anti-VEGF therapies. The Company recently announced the positive result of the GLP-Tox studies of PMC-403 and will submit an IND dossier for an ophthalmological trial in 3T22.
PMC-309 is a novel V-domain Ig Suppressor of T cell Activation (VISTA) antagonist antibody being developed for the treatment of various tumor types. By inhibiting VISTA, an immune checkpoint receptor primarily expressed on MDSCs (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells), it may play a central role in maintaining the immunosuppressive environment around tumor cells . In non-clinical studies, it was found that PMC-309 can promote both innate immunity (monocyte activation, M1 macrophage proliferation) and adaptive immunity (T-cell activation) unlike existing drugs that show significant changes only in adaptive immunity. PMC-309 may offer a novel treatment strategy in the field of immuno-oncology as it can be used in combination with other drugs to improve their low response rates. The in vivo study showed that PMC-309 demonstrated significant improvement in tumor growth inhibition when used with anti-PD1 drug. The company plans to submit a clinical trial application to the Australian HREC (Human Research Ethics Committee) for a Phase I clinical trial in 3Q22.
About PharmAbcine Inc.
PharmAbcine is a clinical-stage biotechnology company focused on the development of fully human antibody therapeutics to treat neovascular disorders, tumors and other medically unmet diseases. It provides therapeutic antibodies for a wide range of indications ranging from oncology, immuno-oncology, ophthalmology, pulmonology to renal pathology.
PharmAbcine has its own HuPhage library and an innovative selection system. PharmAbcine’s advanced 3G expression system enables high levels of antibody production and consistent reproducibility. Through these state-of-the-art technology platforms, it provides state-of-the-art antibody generation services.
PharmAbcine also has unique know-how in the field of antibody production, early drug development and clinical development.
For more information about PharmAbcine, visit http://www.pharmabcine.com or follow us on Youtube and Linkedin.
For licensing agreements, co-development and research collaboration or antibody discovery requests, please contact:
Business development team
Email: [email protected]
Office line: +82 70 4279 5100
For Investor Relations and Public Relations, please contact:
IR/PR team
Sungjun ParkAssociated
Email: [email protected]
Office line: +82 70 4270 2637
View original content to download multimedia: https://www.prnewswire.com/news-releases/pharmabcine-to-participate-in-jefferies-global-healthcare-conference-and-bio-international-convention-301544534.html
SOURCE PharmAbcine